Back to search results

Genetic Studies of Familial Lymphoproliferative Disorders

This observational study aims to understand the genetic causes of certain blood cancers like lymphoma, leukemia, and multiple myeloma. Researchers are collecting DNA and immune cells (lymphocytes) from individuals and families affected by these conditions. You might be eligible if you have a personal or family history of lymphoma, leukemia, multiple myeloma, or related disorders. The goal is to build a collection of samples to help future genetic research into these diseases. This study is not testing a specific treatment, but rather gathering information to help scientists learn more about these conditions. The study plans to enroll about 500 participants.

Study design
This is an observational study, meaning it collects information without testing a specific treatment. It plans to include about 500 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary goal of collecting samples is measured at 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT00582621

Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders

Recruiting
Not specifiedAll AgesObservational
Memorial Sloan Kettering Cancer Center
~500 participants
Updated 2026-01-23 on ClinicalTrials.gov

At a glance

Recruiting sites
6 of 6 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To establish a collection of DNA and frozen lymphocytes for the purpose of facilitating genetic laboratory investigations of familial lymphoid neoplasms.
Measured over 2 years

Conditions

Lymphoma
Leukemia
Multiple Myeloma
Colon Cancer
Renal Cancer

Explore related trials

Colon CarcinomaHematologic NeoplasmKidney CarcinomaLeukemiaLymphomaMultiple MyelomaPancreatic CarcinomaProstate CarcinomaSolid Neoplasm

Where it's being run

6 sites across 2 states
New York4
New Jersey2

Study leadership

  • Kenneth Offit, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Kenneth Offit, MD
646-888-4050
Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Individuals with a personal and/or family history of lymphoma or lymphoproliferative disease B-cell malignancies, or multiple myeloma referred for study participation, or MSK patients referred from to the MSKCC outpatient clinics of the Lymphoma, Multiple Myeloma, or Leukemia Services in the Department of Medicine in consultation for treatment who are found on routine history or through a Family History Questionnaire (FHQ) (Appendix A). Individuals who have relatives or members of successive generations of the family affected with Hodgkin's disease, non-Hodgkin's lymphoma, lymphoid leukemia, multiple myeloma other lymphoproliferative disease prostate or pancreatic cancers, or other conditions suggesting hereditary cancer at the discretion of the MSKCC Principal Investigator. Patients with lymphoma, associated with colon and renal cancer will be eligible for DNA storage through this protocol. Family members or probands with Hodgkin's disease who are women who received therapeutic irradiation for Hodgkin's disease" or who developed secondary cancers after Hodgkin's disease are also eligible for participation.
Family members of probands including patients, sisters, brothers, halfbrothers and sisters, sons, daughters, grandparents, as well as aunts and uncles are also eligible. An effort will be made to ascertain all living affected and unaffected living relatives in the affected lineage. An emphasis will be on affected sibling pairs and both parents, if alive.
As this study involves research that presents no greater than minimal risk to children (see Sec. 46.404 of Federal Regulations part 46), minors are also eligible for participation. The assent of any minor should be obtained before the patient is enrolled into this study, as well as the consent of the legal guardian.

Exclusion

N/A

What this trial measures

  • To establish a collection of DNA and frozen lymphocytes for the purpose of facilitating genetic laboratory investigations of familial lymphoid neoplasms.2 years